IXIARO: Essential Protection Against Japanese Encephalitis for Travelers

Responsible: Julian Krause, ad hoc news editorial team. Checked on 05.07.2026, 10:30 AM. Details in the imprint.

Valneva’s IXIARO sits in a refrigerator, the small vial slightly fogging up as travel medicine specialist Dr. Anna Scholz removes it from the packaging. She explains to a couple planning a trip to Southeast Asia how this vaccine protects against Japanese Encephalitis, gently tapping the hard plastic container. The moment before the needle touches the skin is quiet and focused.

What IXIARO Does

IXIARO is an inactivated vaccine against Japanese Encephalitis, transmitted by mosquitoes, developed by Valneva and approved as a travel vaccine in many countries. According to Valneva, the vaccine is based on an inactivated, purified JE virus and is administered intramuscularly, typically in the upper arm muscle. The European Medicines Agency notes that IXIARO is approved for adults and children starting from 2 months of age, significantly broadening its target audience beyond the classic business traveler.

The standard primary immunization consists of two doses given 28 days apart, with the last dose needing to be completed at least one week before potential exposure. For individuals at ongoing risk, a booster shot is recommended after several years, as detailed in the technical information and the recommendations of national vaccination commissions. Clinical studies have demonstrated the vaccine’s effectiveness, including evidence of protective antibody titers, referencing Phase III data in scientific publications. These studies show that the majority of vaccinated individuals are seroprotective after the primary immunization.

Target Audience: Long-Distance Travelers and Expatriates

Typical users of IXIARO are individuals planning to spend extended periods in endemic areas, such as parts of China, India, Nepal, Indonesia, or other countries in South and Southeast Asia. Travel doctor Dr. Scholz reports that families with children and business expats often seek this vaccine when visiting rural regions or traveling during the rainy season. Short trips to major cities without exposure to nature typically do not warrant a recommendation unless advised by the national vaccination commission.

In Germany, the Foreign Office and travel medicine societies recommend an individual risk assessment. Those who sleep with open windows at night, stay in camping sites, or work outdoors have a different risk profile compared to those mainly residing in air-conditioned hotels. This differentiation plays a significant role in consultations, and IXIARO is only recommended when a relevant exposure risk is present. In some Asian countries, protection against Japanese Encephalitis is included in the children’s vaccination program, where different vaccines are used; IXIARO primarily caters to travelers from Europe and North America.

Approval, Safety, and Usage

The European Medicines Agency highlights in its approval summary that IXIARO is based on a formal benefit-risk assessment process that considers the severity of Japanese Encephalitis and available alternatives. It is noted that JE is a rare but potentially fatal brain infection, and some patients develop lasting neurological damage. The vaccine uses an inactivated virus, distinguishing it from live vaccines and addressing specific patient groups.

The most common side effects listed in the technical information include local reactions at the injection site, such as redness, pain, or swelling, along with systemic effects like headaches, fatigue, or a mild temperature increase. Travel medicine practitioners carefully observe how patients respond to the first dose and recommend a second one only if no serious adverse events occur. Individuals with known allergies to vaccine components or acute severe illnesses should be vaccinated cautiously, following guidelines.

Valneva’s Portfolio Role

For Valneva, a France-based vaccine specialist, IXIARO is a vital product within its travel vaccine segment. The company reports in its financial statements that the travel vaccine sector, including IXIARO and other products like the cholera vaccine, generates substantial revenue and shows a recurring demand. Following the reopening of many borders after the pandemic, interest in travel consultations and corresponding vaccinations has surged.

Valneva’s management, led by CEO Thomas Lingelbach, emphasizes in presentations to analysts that stable products like IXIARO provide a solid foundation for financing clinical development programs in other indications. While platform projects and new vaccine candidates still carry uncertainties, an established travel vaccine offers more predictable cash flows. For investors, these established products may not make headlines, but they stabilize the balance sheet and support the market valuation of Valneva SE stock.

Availability and Pricing Structure

IXIARO is available in several European countries, including Germany, Austria, and the United Kingdom, through travel and tropical medicine practitioners, vaccination centers, and often larger general practices. In Germany, it is typically dispensed through pharmacies upon medical prescription, with the price per vial varying by country and tax system, ranging around 100 Euros or slightly more or less. The exact pricing structure depends on local regulations, wholesaler margins, and potential reimbursements from health insurance providers.

Many statutory health insurance providers in Germany do not routinely cover vaccinations for private foreign travel; however, some offer reimbursement programs for travel vaccinations or bonus schemes. Travelers should check beforehand whether and to what extent reimbursement is possible. In other markets, such as Scandinavia or the UK, the cost issue is handled differently, often featuring specialized travel vaccination clinics with package prices. This variety in reimbursement systems presents a challenge for Valneva’s planning of distribution and demand.

This article was AI-assisted and editorially reviewed. Product information is not guaranteed; prices and availability may change at short notice. This is not an investment advisory, nor is it a recommendation to buy or sell. Trading is associated with risks, including total loss.